For selected tumor types, cyclin D1 has been postulated as a potential target for therapeutic intervention (e.g. pancreatic and breast cancer) [53-55], and how the disparate functions of cyclin D1b may influence outcome should likely be incorporated as a major consideration. The gene discussed is CCND1; the disease is breast cancer.